Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Fallopian Tube Neoplasms 3Ovarian Neoplasms 2Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 166Carboplatin 132Cisplatin 81Paclitaxel 78Gemcitabine 77Pemetrexed 72Bevacizumab 63Docetaxel 54Fluorouracil 49Oxaliplatin 48Dexamethasone 46durvalumab 43atezolizumab 39Leucovorin 39130-nm albumin-bound paclitaxel 39Capecitabine 37Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Prednisone 28Lenalidomide 28enzalutamide 27pomalidomide 25Letrozole 25Irinotecan 25daratumumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × mirvetuximab soravtansine × 30 days × Clear all
NCT07059845 2026-06-04

FLORENZA

AbbVie

Phase 2 Recruiting
400 enrolled
Gynecologic

Ovarian Neoplasms

NCT05445778 2026-06-02

GLORIOSA

AbbVie

Phase 3 Active not recruiting
520 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06890338 2026-05-29

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AbbVie

Phase 2 Recruiting
140 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06682988 2026-05-26

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

AbbVie

Phase 2 Recruiting
110 enrolled
Gynecologic

Fallopian Tube Neoplasms

NCT04274426 2026-05-13

MIROVA

AGO Research GmbH

Phase 2 Active not recruiting
136 enrolled
Gynecologic

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡